Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital

Non-dilutive committed capital extends cash runway into at least 2024 Facility strengthens balance sheet through anticipated commercial launches of Axsome’s two lead CNS product candidates NEW YORK,...
September 24, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine

Significantly faster time to pain relief as compared to rizatriptan (p<0.001) Significantly less relapse of migraine pain as compared to rizatriptan (p=0.001) Benefits demonstrated in...
September 21, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting

Single Phase 3 trial to be conducted to support an NDA filing of AXS-12 in the treatment of narcolepsy; trial initiation anticipated 1Q 2021 Extensive patient safety database, previously obtained...
September 17, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation

Data from MOMENTUM Phase 3 trial to be presented at the 2020 AAN Science Highlights Platform NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
September 14, 2020 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder

Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
September 10, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
September 08, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
September 03, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 31, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting

Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation Initiation of Phase 3, placebo-controlled,...
August 28, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...